- Arvinas Inc to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program Call TranscriptDec 06, 2023
- Arvinas Inc To Host ESMO Data Presentation Call TranscriptOct 22, 2023
- Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 28, 2023
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Arvinas Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Arvinas Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Arvinas Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Arvinas Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- Arvinas Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Arvinas, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 01:30 PM TranscriptJan 11, 2023
- Arvinas Inc SABCS Event TranscriptNov 22, 2022
- Arvinas Inc at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- Arvinas Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Arvinas Inc at Citi BioPharma Conference TranscriptSep 08, 2022
- Arvinas Inc at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Arvinas Inc at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Arvinas Inc to Discuss the Phase 1 Dose Escalation Data and Interim Data from the Phase 2 ARDENT Trial TranscriptFeb 17, 2022
- Arvinas Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 10, 2022
- Arvinas Inc ARV-471 Program Update Call TranscriptDec 10, 2021
- Arvinas Inc and Pfizer Inc Announce ARV-471 Collaboration- Conference Call TranscriptJul 22, 2021
- Arvinas Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Arvinas Inc at UBS Global Healthcare Virtual Conference TranscriptMay 25, 2021
- Arvinas Inc ASCO Data Conference Call TranscriptMay 29, 2020
- Arvinas Inc Conference Call TranscriptOct 23, 2019
Arvinas Inc Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to the Arvinas conference call. (Operator Instructions). I would now like to turn the call over to Randy Teel, vice president of corporate development at Arvinas. Please proceed.
Thank you very much. Good morning, everyone, and thank you for joining us today to review initial clinical data from our PROTAC protein degrader platform which will be presented today at the 2nd Targeted Protein Degradation Summit in Boston. You can access the relevant press release, 8-K filing and the slides that will be presented at 11:30 AM today in the Investors section of our website at Arvinas.com.
With me today are President and Chief Executive Officer, John Houston; Chief Medical Officer, Ron Peck; Chief Scientific Officer, Ian Taylor; and Chief Financial Officer, Sean Cassidy.
Before we begin the call I would like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)